Proteomics-based analysis of differentially expressed proteins in the CXCR1-knockdown gastric carcinoma MKN45 cell line and its parental cell

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 10, 2013, Pages 857-866

  Hu, Wanming ^a   Wang, Junpu ^b   Luo, Gengqiu ^b   Luo, Baihua ^b   Wu, Chang ^b   Wang, Weiyuan ^b   Xiao, Yan ^b   Li, Jinghe ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CXCR1; Gastric carcinoma; Proteomics

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; TRANSCRIPTOME; TUMOR PROTEIN;

ADENOCARCINOMA; ARTICLE; CXCR1; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; METHODOLOGY; PROTEOMICS; STOMACH CARCINOMA; STOMACH TUMOR; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

CXCR1; GASTRIC CARCINOMA; PROTEOMICS;

ADENOCARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASM PROTEINS; PROTEOMICS; RECEPTORS, INTERLEUKIN-8A; STOMACH NEOPLASMS; TRANSCRIPTOME; UP-REGULATION;

EID: 84888615968     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt086     Document Type: Article

References (72)

1. Jing JJ, Liu HY, Hao JK, Wang LN, Wang YP, Sun LH and Yuan Y. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010.World J Gastroenterol 2012, 18: 1262-1269.
2. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006, 12: 17-20.
3. Feng J, Wu YF, Xu HM, Wang SB and Chen JQ. Prognostic significance of the metastatic lymph node ratio in T3 gastric cancer patients undergoing total gastrectomy. Asian Pac J Cancer Prev 2011, 12: 3289-3292.
4. Nathan C and Ding A. Nonresolving inflammation. Cell 2010, 140: 871-882.
5. Mantovani A. Cancer: inflaming metastasis. Nature 2009, 457: 36-37.
6. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R and Forbes B, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011, 71: 5522-5534.
7. Wendel C, Hemping-Bovenkerk A, Krasnyanska J, Mees ST, Kochetkova M, Stoeppeler S and Haier J. CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model. PLoS ONE 2012, 7: e30046.
8. Marchesi F, Grizzi F, Laghi L, Mantovani A and Allavena P. Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system. Curr Pharm Des 2012, 18: 2432-2438.
9. Balkwill FR. The chemokine system and cancer. J Pathol 2012, 226: 148-157.
10. Lazennec G and Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. TrendsMolMed 2010, 16: 133-144.
11. Waugh DJ and Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14: 6735-6741.
12. Zhang Y, Wang L, Zhang M, Jin M, Bai C and Wang X. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol 2012, 227: 35-43.
13. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M and Wicinski J, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010, 120: 485-497.
14. Singh S, Nannuru KC, Sadanandam A, Varney ML and Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 2009, 100: 1638-1646.
15. Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R and Singh RK. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett 2011, 300: 180-188.
16. Verbeke H, Geboes K, Van Damme J and Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 2012, 1825: 117-129.
17. Wang JP, Hu WM, Wang KS, Luo BH, Wu C, Chen ZH and Luo GQ, et al. Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma. Exp Ther Med 2012, 4: 55-60.
18. Wang JP, Hu WM, Wang KS, Yu J, Luo BH, Wu C and Chen ZH, et al. Expression of C-X-C chemokine receptor types 1/2 in patients with gastric carcinoma: clinicopathological correlations and significance. Oncol Lett 2013, 5: 574-582.
19. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J and Stratford IJ, et al. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007, 26: 7333-7345.
20. Sharma B, Singh S, Varney ML and Singh RK. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets 2010, 14: 435-442.
21. Li MQ, Luo XZ, Meng YH, Mei J, Zhu XY, Jin LP and Li DJ. CXCL8 enhances proliferation and growth and reduces apoptosis in endometrial stromal cells in an autocrine manner via a CXCR1-triggered PTEN/AKT signal pathway. Hum Reprod 2012, 27: 2107-2116.
22. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G and Howell SJ, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res 2013, 19: 643-656.
23. Xu Y, Diao Y, Qi S, Pan X, Wang Q, Xin Y and Cao X, et al. Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis. Cell Signal 2013, 25: 1176-1185.
24. Kaigorodova EV, Ryazantseva NV, Novitskii VV, Maroshkina AN and Belkina MV. Effects of HSP27 chaperone on THP-1 tumor cell apoptosis. Bull Exp Biol Med 2012, 154: 77-79.
25. Charette SJ, Lavoie JN, Lambert H and Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol Cell Biol 2000, 20: 7602-7612.
26. Choi SR, Lee SA, Kim YJ, Ok CY, Lee HJ and Hahm KB. Role of heat shock proteins in gastric inflammation and ulcer healing. J Physiol Pharmacol 2009, 60(Suppl 7): 5-17.
27. Tand D, Tang S, Luo Z, Wu C, Zhang Z, Zhao P and Shi B, et al. The expression of heat shock protein 27 in gastric cancer. Tumor 2009, 29: 272-275.
28. Rong F, Li L, Hou H, Wang Y and Wang M. Expression and significance of HSP27 in human gastric cancer and precancerous conditions. Shanxi Med J 2009, 38: 984-986.
29. Yang YX, Sun XF, Cheng AL, Zhang GY, Yi H, Sun Y and Hu HD, et al. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol 2009, 135: 181-189.
30. Jin YH, Kita K, Sun Z, Tong XB, Nie H and Suzuki N. The roles of HSP27 and annexin II in resistance to UVC-induced cell death: comparative studies of the human UVC-sensitive and -resistant cell lines RSa and APr-1. Biosci Biotechnol Biochem 2009, 73: 1318-1322.
31. Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K and Rozsas A, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multiinstitutional case-control study. Clin Chim Acta 2012, 413: 1115-1120.
32. Colotti G, Zamparelli C, Verzili D, Mella M, Loughrey CM, Smith GL and Chiancone E. The W105G and W99G sorcin mutants demonstrate the role of the D helix in the Ca(2+)-dependent interaction with annexin VII and the cardiac ryanodine receptor. Biochemistry 2006, 45: 12519-12529.
33. Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K and Sugisaki Y, et al. Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol 2006, 111: 29-38.
34. Wood RJ, Tchack L, Angelo G, Pratt RE and Sonna LA. DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics 2004, 17: 122-129.
35. Chuthapisith S, Layfield R, Kerr ID, Hughes C and Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2007, 30: 1545-1551.
36. Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, Lombardi V and Matassa DS, et al. Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(2+) homeostasis. Cancer Res 2011, 71: 7659-7669.
37. Yang YX, Xiao ZQ, Chen ZC, Zhang GY, Yi H, Zhang PF and Li JL, et al. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006, 6: 2009-2021.
38. Deng L, Su T, Leng A, Zhang X, Xu M, Yan L and Gu H, et al. Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol 2010, 27: 1102-1108.
39. Landriscina M, Laudiero G, Maddalena F, Amoroso MR, Piscazzi A, Cozzolino F and Monti M, et al. Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res 2010, 70: 6577-6586.
40. He Q, Zhang G, Hou D, Leng A, Xu M, Peng J and Liu T. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 2011, 25: 237-243.
41. Han SP, Tang YH and Smith R. Functional diversity of the hnRNPs: past, present and perspectives. Biochem J 2010, 430: 379-392.
42. Konig J, Zarnack K, Rot G, Curk T, Kayikci M, Zupan B and Turner DJ, et al. iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat Struct Mol Biol 2010, 17: 909-915.
43. Bomsztyk K, Denisenko O and Ostrowski J. hnRNP K: one protein multiple processes. Bioessays 2004, 26: 629-638.
44. Fukuda T, Naiki T, Saito M and Irie K. hnRNP K interacts with RNA binding motif protein and functions in the maintenance of cellular ATP level during stress conditions. Genes Cells 2009, 14: 113-128.
45. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D and Adam RM, et al. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res 2009, 69: 2210-2218.
46. Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, Pazin MJ and Schmidt EV. hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol 2005, 25: 6436-6453.
47. Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, Bagheri-Yarmand R and Mendelsohn J, et al. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem 2001, 276: 9699-9704.
48. Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F and Balbi C. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines. Prostate 2011, 71: 1466-1479.
49. Zhou R, Shanas R, Nelson MA, Bhattacharyya A and Shi J. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int J Cancer 2010, 126: 395-404.
50. Guo Y, Zhao J, Bi J, Wu Q,Wang X and Lai Q. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol 2012, 5: 37.
51. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C and Murray GI. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006, 95: 921-927.
52. Wang F, Zhang P, Shi C, Yang Y and Qin H. Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol 2012, 29: 1780-1788.
53. Zhao Y, Jin X, Tian T and Yu DH. Expression of hnRNPK in gastric carcinoma and its relationship with Helicobacter pylori L-form infection. Zhonghua Zhong Liu Za Zhi 2011, 33: 759-763.
54. Ebert MP, Lamer S, Meuer J, Malfertheiner P, Reymond M, Buschmann T and Rocken C, et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Proteome Res 2005, 4: 586-590.
55. Xiao Y, Zhang Q, Zhao H, Lou X and He Y. Expressions of C-myc and hnRNPK in gastric intraepithelial neoplasia tissues. J Basic Clin Oncol 2010, 23: 478-479.
56. Zhang Q, Xiao Y, Zhao C, Zhao H, Lou X and He Y. Expressions of c-myc and hnRNP K and their clinical significance in human gastric adenocarcinoma tissues. Chin J Cancer Prev Treat 2009, 14: 1661-1663.
57. Boissan M, Dabernat S, Peuchant E, Schlattner U, Lascu I and Lacombe ML. The mammalian Nm23/NDPK family: from metastasis control to cilia movement. Mol Cell Biochem 2009, 329: 51-62.
58. Lombardi D, Lacombe ML and Paggi MG. nm23: unraveling its biological function in cell differentiation. J Cell Physiol 2000, 182: 144-149.
59. Jarrett SG, Novak M, Harris N, Merlino G, Slominski A and Kaetzel DM. NM23 deficiency promotes metastasis in a UV radiation-induced mouse model of human melanoma. Clin Exp Metastasis 2013, 30: 25-36.
60. Novak M, Jarrett SG, McCorkle JR, Mellon I and Kaetzel DM. Multiple mechanisms underlie metastasis suppressor function of NM23-H1 in melanoma. Naunyn Schmiedebergs Arch Pharmacol 2011, 384: 433-438.
61. Li X, Hu R, Qu J, He Q, Chen Y, Li J and Ye X, et al. Identification of nm23-H1 as a metastatic suppressor and prognostic factor in nasopharyngeal carcinoma by proteomic analysis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2012, 37: 17-26.
62. Dong SW, Wang L, Sui J, Deng XY, Chen XD, Zhang ZW and Liu X, et al. Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: correlations with metastasis. Mol Diagn Ther 2011, 15: 211-219.
63. Lu W, Li YH, He XF, Mo YY and Zhu ZY. Transcatheter arterial chemoembolization enhances expression of Nm23-H1 and TIMP-2 in the tumor tissue of patients with hepatocellular carcinoma. Hepatogastroenterology 2011, 58: 558-564.
64. Luo M, Zhu D, Gong L, Qiu X, Zu L, Sun L and Wu Z, et al. Lentivirusmediated stable silencing of nm23-H1 gene in lung cancer cells and the influence on biological behavior. Zhongguo Fei Ai Za Zhi 2012, 15: 139-145.
65. Andolfo I, De Martino D, Liguori L, Petrosino G, Troncone G, Tata N and Galasso A, et al. Correlation of NM23-H1 cytoplasmic expression with metastatic stage in human prostate cancer tissue. Naunyn Schmiedebergs Arch Pharmacol 2011, 384: 489-498.
66. Carotenuto M, Pedone E, Diana D, de Antonellis P, Dzeroski S, Marino N and Navas L, et al. Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. Sci Rep 2013, 3: 1351.
67. Lee JH, Marshall JC, Steeg PS and Horak CE. Altered gene and protein expression by Nm23-H1 in metastasis suppression. Mol Cell Biochem 2009, 329: 141-148.
68. Boissan M and Lacombe ML. NM23, an example of a metastasis suppressor gene. Bull Cancer 2012, 99: 431-440.
69. Wang LB, Jiang ZN, Fan MY, Xu CY, Chen WJ and Shen JG. Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer. World J Gastroenterol 2008, 14: 1612-1616.
70. Baorui L, Xueyong Z and Jie D. Expression of nm23 protein in metastatic gastric cancer. Chin J Pathol 1996, 5: 52.
71. Mizuuchi E, Semba S, Kodama Y and Yokozaki H. Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer 2009, 124: 1802-1810.
72. Kim TM, Jeong HJ, Seo MY, Kim SC, Cho G, Park CH and Kim TS, et al. Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Clin Cancer Res 2005, 11: 79-86.